Immune Globulin Subcutaenous (Human), 20%
A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases
Sponsor: Baxalta now part of Shire
This PHASE2/PHASE3 trial investigates Primary Immunodeficiency Diseases (PID) and is currently completed. Baxalta now part of Shire leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 5 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2019 — May 2020 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE2_PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Nov 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .